Author: Peter Matasek
Estimated read time: 5 minutes
Publication date: 23rd Mar 2020 12:30 GMT+1
Try to explain what Myomo is doing:
Myomo is a medical robotics company that offers increased arm and hand functionality for those suffering from neurological disorders and upper-limb paralysis. Based on patented technology developed at MIT, and Harvard Medical School, Myomo develops and markets the MyoPro product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuro-muscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
The MyoPro is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Published research shows a clinically significant instantaneous reduction in upper extremity impairment through the use of MyoPro.
MyoPro is referred for patients ages twelve and above at many leading rehabilitation facilities, including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute, Loma Linda Medical Center and twenty VA hospitals, among others. It is fitted and delivered through clinicians nationwide, and nearly 1,000 have been used by patients.
Myomo has many amazing patients who have overcome obstacles related to their injuries, and are living independent lives with the help of their MyoPro devices. Our customers range from all ages, geographic regions, and demographics. We’re helping a multitude of audiences, including those who are paralyzed due to a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuro-muscular disability such as amyotrophic lateral sclerosis or multiple sclerosis.
Zeke, an adolescent Myomo patient from the Ohio area, now attending college, was in an ATV accident over ten years ago. His injuries were dire, leaving him in the hospital for months with brain, spinal cord and brachial plexus injuries. Although he made a remarkable recovery, his injuries were too extensive in his shoulder, leaving his left arm completely useless.
Zeke’s family continued to look for a solution and came across the MyoPro brace. Since getting fitted with the device, he’s now able to complete simple tasks he once took for granted such as skateboarding with friends or helping his mom with chores. Zeke is just one of many success stories from Myomo patients who have successfully regained the use of a once paralyzed limb.
Myomo currently has 53 employees total. Beyond the headquarters in Cambridge, Massachusetts, Myomo employees span more than a dozen states around the United States in various roles.
In both our field clinical positions and our headquarters engineering positions, our standards and requirements are very high, so finding qualified team members is never easy. But we are fortunate to have a product which is innovative and exciting and truly life-changing for many people, and a culture that is high-energy and very supportive, and that attracts great candidates.
Patients suffering from upper extremity weakness secondary to neurological injuries (e.g. stroke, brachial plexus injury, ALS, head / spinal cord injury, cerebral palsy, etc.) face a significant, historically-unmet need for restorative, powered bracing. This patient population often spends years fully exploring the potential benefits of traditional rehabilitation techniques and less sophisticated medical devices before reaching a point where progress stalls because of time constraints, limited insurance resources, as well as limits shortcomings in traditional technology. MyoPro is currently used by hundreds of adults and adolescents. Using innovative technology, MyoPro is light enough for children ages twelve and up to be able to use the device without weighing down even smaller frames. Myomo’s adolescent brace launched in June 2018.
Later this year, Myomo will launch a brand-new device specifically designed for children under 12 and petite adults, MyoPal, which will be the only device available for ages five and up that helps to restore and regain arm and hand function.
Given most of Myomo’s work to date has been with adults, entering the pediatric market will be a whole new venture. The new design takes most of the weight off the child’s arm so it’s easier to move around, perform daily tasks and play. The MyoPal transfers the weighted elements of the device into a sleek backpack, a product children are more suited to handle.
Myomo is already partnering with some of the top pediatric hospitals and agencies across the country including Boston’s Children’s, Cleveland Clinic, United Cerebral Palsy and Shriners to bring the MyoPal directly to their patients.
Our segment is powered upper limb orthoses, and Myomo has the only products in that segment, protected by a very strong patent portfolio. Trends that we are advancing include lighter weight, smaller devices for smaller children, improved hand functionality, software advances that enable smoother, more natural movement and support for games that make therapy more fun for children and adults alike.
Social Media of Myomo:
Disclaimer: The writer is an experienced financial consultant who writes for Finscreener.org. The observations he makes are his own and are not intended as investment or trading advice.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.